Squarepoint’s Contineum Therapeutics CTNM Stock Holding History

Squarepoint’s Portfolio CTNM Stock Details CTNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$167K	Buy	12,480 +744	+6%	+$11.1K	﹤0.01%	4116
2026 Q2	$192K	Sell	11,736 -48,108	-80%	-$631K	﹤0.01%	4078
2026 Q1	$782K	Buy	+59,844	New	+$803K	﹤0.01%	2981
2025 Q4	–	Sell	-13,086	Closed	-$154K	–	5018
2025 Q3	$154K	Sell	13,086 -76,328	-85%	-$615K	﹤0.01%	4021
2025 Q2	$355K	Sell	89,414 -41,613	-32%	-$181K	﹤0.01%	3557
2025 Q1	$915K	Sell	131,027 -86,212	-40%	-$784K	﹤0.01%	2751
2024 Q4	$3.18M	Sell	217,239 -132,761	-38%	-$2.1M	﹤0.01%	2011
2024 Q3	$6.7M	Buy	350,000 +200,000	+133%	+$3.83M	0.01%	1221
2024 Q2	$2.64M	Buy	+150,000	New	+$2.42M	﹤0.01%	1834

Other funds holding CTNM

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Red Tree Management Redwood City, California $117M AUM 89.68% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Silverarc Capital Management Boston, Massachusetts $854M AUM 179.73% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Squarepoint's CTNM Position: Q3 2026 in Review

Squarepoint increased its Contineum Therapeutics (CTNM) stake by 6.3% in Q3 2026, buying an estimated $11.1K and bringing the position to 12,480 shares worth $167K. The position accounts for ﹤0.01% of the portfolio, ranked #4116.

Squarepoint first reported a position in CTNM in Q2 2024 and has held it in 9 quarters since. The position peaked at $6.7M in Q3 2024. 46 funds tracked by Wall St. Rank hold CTNM as of Q3 2026.

Squarepoint held 12,480 shares of Contineum Therapeutics worth $167K as of Q3 2026.
Squarepoint bought 744 Contineum Therapeutics shares in Q3 2026, an estimated $11.1K.
Contineum Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q3 2026, its #4116 holding.
Squarepoint first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 9 quarters since.
Squarepoint's Contineum Therapeutics position peaked at $6.7M in Q3 2024.
46 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.